Correlation Between Idiopathic Parkinson’s Disease and Diabetes Mellitus

Overview

Correlation between Idiopathic Parkinson's disease and diabetes mellitus in Egyptian Elderly Patients

Full Title of Study: “Investigation of the Possible Correlation Between Idiopathic Parkinson’s Disease and Diabetes Mellitus in Egyptian Elderly Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: June 2019

Detailed Description

1. Record RBDSQ ("Rapid eye movement Sleep" Behavior Disorder Screening Questionnaire) total score difference between Group 1 and Group 2 . 2. Oral glucose tolerance test will be performed and compared between Group 3 and Group 4. 3. Association between glucose level and motor complication of L-dopa among Idiopathic Parkinson's patients using Unified Parkinson's Disease Rating Scale (UDPRS).

Arms, Groups and Cohorts

  • Idiopathic Parkinson’s
    • Oral glucose tolerance test The Unified Parkinson’s Disease Rating Scale (UDPRS).
  • Diabetics receive sulphonylurea group
    • Record RBDSQ (“Rapid eye movement Sleep” Behavior Disorder Screening Questionnaire) total score
  • Diabetics on sulphonylurea and metformin
    • Record RBDSQ (“Rapid eye movement Sleep” Behavior Disorder Screening Questionnaire) total score
  • Healthy
    • Record RBDSQ (“Rapid eye movement Sleep” Behavior Disorder Screening Questionnaire) total score Oral glucose tolerance test

Clinical Trial Outcome Measures

Primary Measures

  • UPDRS (Unified Parkinson’s Disease Rating) Scale)
    • Time Frame: Baseline
    • Association between glucose level and motor complication of L-dopa among Idiopathic , , Parkinson’s patients using Unified Parkinson’s Disease Rating Scale (UDPRS)., high scores mean worsen condition
  • Oral Glucose Tolerance Test
    • Time Frame: 0, 0.5 hour , 1 hour, 1.5 hour , 2 hour
    • Between Idiopathic Parkinson’s patients and the Control group
  • RBDSQ (“Rapid eye movement Sleep” Behavior Disorder Screening Questionnaire)
    • Time Frame: Baseline
    • among Diabetic Patients, total score 13 , high scores mean worsen condition

Participating in This Clinical Trial

Inclusion Criteria

1. Diabetic Patients 2. Idiopathic Parkinsonism Exclusion Criteria:

1. Secondary Parkinsonism due to stroke, trauma and encephalitis. 2. Drug induced Parkinsonism.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Ain Shams University
  • Collaborator
    • Al-Azhar University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Afnan Awad-Allah Elgnainy, Master student, teaching assistant of Clinical Pharmacy – Ain Shams University
  • Overall Official(s)
    • Afnan Elgnainy, Principal Investigator, AinShams University
  • Overall Contact(s)
    • Afnan Elgnainy, 01061840761, Afnan.elgnainy@pharma.asu.edu.eg

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.